In these cost-effectiveness studies, all participants were patients with T2DM, most of whom were adults with HbA1c level greater than 7% or non-insulin-treated type 2 diabetes (46, 50, 51, 55). This evidence concerns the gene INS and type 2 diabetes mellitus.